signatera breast cancer

Release time ：Dec-18,2024

Signatera for breast cancer is a personalized liquid biopsy technique that targets specific tumor characteristics to detect and monitor minimal residual disease (MRD) in patients with breast cancer. By analyzing circulating tumor DNA (ctDNA) in the patient's blood, this technology offers insights into the genetic alterations of the tumor, assisting physicians in gaining a better understanding of the patient's disease status and in devising tailored treatment strategies.

In the application of Signatera for breast cancer surveillance, physicians initially obtain tumor tissue samples from the patient to identify the tumor's unique genetic mutations. Thereafter, by periodically collecting the patient's blood samples, they check for the presence of genetic mutations identical to those found in the tumor tissue. The detection of ctDNA may indicate that tumor cells are still present in the body or that a recurrence of MRD has occurred. This approach allows for the early identification of tumor recurrence, enabling timely adjustments to treatment strategies.

For breast cancer patients, regular Signatera testing can provide a clearer understanding of their disease status and offer valuable information for physicians to create more precise treatment plans. However, it is important to recognize that Signatera testing should not entirely replace conventional imaging and other laboratory tests; rather, it should be considered a complementary tool in conjunction with other diagnostic and monitoring methods. Additionally, patients undergoing Signatera testing should adhere to their physician's guidance and refrain from interpreting test results independently to prevent unnecessary anxiety and misinterpretation.